

Title: High-flow nasal cannula vs non-invasive ventilation in acute hypoxia: Propensity score matched study

Authors: Elizabeth S Munroe, MD, MSc¹, Ina Prevalaska, MD², Madison Hyer, MS,³ William J Meurer, MD, MS², Jarrod M Mosier, MD^{4,5}, Mark A. Tidswell, MD⁶, Hallie C Prescott, MD, MSc^{1,7} Lai Wei, PhD, MS³, Henry Wang, MD, MPH, MP⁸, Christopher M Fung, MD MS²

- 1- Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan
- 2- Department of Emergency Medicine, University of Michigan, Ann Arbor, Michigan
- 3- Center for Biostatistics, The Ohio State University, Columbus, OH
- 4- Department of Emergency Medicine, University of Arizona College of Medicine, Tucson, Arizona
- 5- Division of Pulmonary, Allergy, Critical Care and Sleep, Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona
- 6- Division of Pulmonary and Critical Care, Department of Medicine, University of Massachusetts Chan Medical School – Baystate Medical Center, Springfield, MA
- 7- VA Center for Clinical Management Research, Ann Arbor, Michigan
- 8- Department of Emergency Medicine, The Ohio State University, Columbus, OH

Correspondence:

Elizabeth S Munroe, MD, MSc
6301 Medical Science Research Building III, SPC 5642
Ann Arbor, MI 48109-5360
Phone: (734) 763-2246
Email: munroeel@med.umich.edu

Word counts

Text: 3,076
Abstract: 250
Figures/Tables: 5
This paper has an online supplement.

Running title: Comparison of non-invasive respiratory support

Descriptor: 4.13 Ventilation: Non-Invasive/Long-Term/Weaning

Conflicts of Interest: JMM has received travel support from Fisher & Paykel.

Funding: Author ESM was supported by Grant Number T32 HL 007749 (Multidisciplinary Training Program in Lung Disease) and Grant Number L30 HL 170379 (Loan Repayment Award) from the National Institutes of Health. This work was supported in part by a grant from NIH (NINDS and NHLBI) for infrastructure for the Clinical Coordinating Center for the Strategies to Innovate EmeRgENcy (SIREN) Care

Clinical Trials Network- 2U24NS100659. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This manuscript does not represent the views of the Department of Veterans Affairs or the US government.

Authors' contributions: ESM, IP, and CMF contributed to the conceptualization and design of the study, data analysis and interpretation, and drafting of this manuscript. MH, WJM, JMM, MAT, WL, HW contributed to the conceptualization of the study, data interpretation, and the writing of the manuscript, including substantive revisions. HCP contributed to data interpretation and the writing of the manuscript, including substantive revisions. All authors have read and approved the final manuscript.

Impact: In this propensity score matched retrospective study of patients with early acute hypoxemic respiratory failure, initial treatment with non-invasive ventilation was superior to high-flow nasal cannula for major adverse pulmonary events, calculated using a Win Ratio. These results underscore the need for novel randomized controlled trials to definitively determine the merits of each non-invasive respiratory support strategy.

1 **Abstract**

2 RATIONALE

3 The optimal treatment for early hypoxemic respiratory failure is unclear, and both high-
4 flow nasal cannula and non-invasive ventilation are used. Determining clinically relevant
5 outcomes for evaluating non-invasive respiratory support modalities remains a
6 challenge.

8 OBJECTIVES

9 To compare the effectiveness of initial treatment with high-flow nasal cannula versus
10 non-invasive ventilation for acute hypoxemic respiratory failure.

11 METHODS

12 We conducted a retrospective cohort study of patients with acute hypoxemic respiratory
13 failure treated with high-flow nasal cannula or non-invasive ventilation within 24 hours of
14 Emergency Department arrival (1/2018-12/2022). We matched patients 1:1 using a
15 propensity score for odds of receiving non-invasive ventilation. The primary outcome
16 was major adverse pulmonary events (28-day mortality, ventilator-free days, non-
17 invasive respiratory support hours) calculated using a Win Ratio.

18 MEASUREMENTS AND MAIN RESULTS

19 1,265 patients met inclusion criteria. 795 (62.8%) received high-flow oxygen and 470
20 (37.2%) received non-invasive ventilation. We propensity score matched 736/1,265
21 (58.2%) patients. There was no difference between non-invasive ventilation vs high-flow

22 nasal cannula in 28-day mortality (17.7% vs 23.1%, $p=0.08$) or ventilator-free days
23 (median [Interquartile Range]: 28 [25, 28] vs 28 [13, 28], $p=0.50$), but patients on non-
24 invasive ventilation required treatment for fewer hours (median 7 vs 13, $p< 0.001$). Win
25 Ratio for composite major adverse pulmonary events favored non-invasive ventilation
26 (1.26, 95%CI 1.06-1.49, $p< 0.001$).

27 CONCLUSIONS

28 In this observational study of patients with acute hypoxemic respiratory failure, initial
29 treatment with non-invasive ventilation was superior to high-flow nasal cannula for major
30 pulmonary adverse events. Evaluation of composite outcomes is important in the
31 assessment of respiratory support modalities.

32

33 Abstract word count: 250/250

34

35 Key words: acute hypoxemic respiratory failure, non-invasive ventilation, oxygen
36 inhalation therapy

37 **Introduction**

38 Acute hypoxemic respiratory failure is a major cause of hospitalizations in the US.^{1,2}
39 There is growing evidence that non-invasive respiratory support may help prevent
40 invasive mechanical ventilation in patients with respiratory failure.³ Traditionally, the
41 primary mode of non-invasive respiratory support was non-invasive positive pressure
42 ventilation (NIV)—continuous positive airway pressure and bilevel positive airway
43 pressure. Over the past decade, accelerated by the COVID-19 pandemic, high-flow
44 nasal canula (HFNC) has emerged as an alternative.^{4,5} NIV and HFNC work through
45 different mechanisms and thus have different benefits and harms. NIV improves
46 oxygenation by increasing mean airway pressure but has the potential to deliver
47 injurious lung volumes which may put patients at risk for patient self-induced lung
48 injury.^{3,6,7} In contrast, HFNC provides less positive pressure ventilatory support than
49 NIV, which may decrease the risk for self-induced lung injury and can help improve
50 patient tolerance.^{7–10}

51
52 The optimal mode of non-invasive respiratory support in acute hypoxemic respiratory
53 failure remains unclear.^{3,11} While guidelines recommend NIV for patients with acute
54 decompensated heart failure and chronic obstructive pulmonary disease exacerbations,
55 these recommendations are based on comparisons of NIV to low-flow oxygen not
56 HFNC.^{3,11} Guidelines further conclude that there is not enough evidence to make a
57 recommendation for HFNC vs NIV in other etiologies of hypoxemic respiratory failure.³
58 The few trials that have directly compared HFNC to NIV have been limited by their focus
59 on narrow populations.^{4,12–15} The largest trial found that for intensive care unit (ICU)

60 patients with pure hypoxemic respiratory failure, HFNC decreased mortality compared
61 to NIV.¹³ However, trials in different populations, e.g., COVID-19 or
62 immunocompromised patients, have yielded conflicting results.^{4,14,15} Furthermore, the
63 generalizability of these trials, particularly to undifferentiated hypoxemic respiratory
64 failure in the emergency department, is limited given patients often require initiation of
65 respiratory support before a clinical diagnosis can be made.

66

67 Additionally, many of the primary outcomes used in trials of non-invasive respiratory
68 support, such as intubation and ventilator-free days, hinge on subjective practice
69 decisions that limit their interpretation.¹⁶ Composite outcomes can help overcome the
70 limitations of potentially subjective individual endpoints. However, traditional
71 approaches to generating composite outcomes lead to loss of the relative importance of
72 key variables (e.g., mortality and need for intubation are treated similarly) and have
73 statistical limitations that prevent the combination of different types of variables (e.g.,
74 binary mortality and continuous ventilator-free days). The Win Ratio, which has been
75 broadly applied in cardiology trials, offers a novel approach to composite outcomes,
76 allowing the combination of different types of variables ranked by clinical relevance.¹⁷
77 The goal of this study was to compare the effectiveness of initial treatment of acute
78 hypoxemic respiratory failure with HFNC versus NIV on a composite outcome of major
79 adverse pulmonary events, calculated using a Win Ratio.

80

81 **Materials and Methods**

82 *Study design and setting*

83 This is a single-center, propensity score matched, retrospective cohort study comparing
84 initial treatment with HFNC vs NIV in patients with acute hypoxemic respiratory failure.
85 This study was approved by the University of Michigan (UM) Institutional Review Board
86 on 3/14/2023 (HUM00232776) as a secondary data use, exempt study.

87

88 *Data Source*

89 We extracted data from the electronic health record (EPIC, Epic systems, Verona,
90 Wisconsin) via queries to our health system's data warehouses (Clarity and Caboodle)
91 and, for respiratory support mode data, directly from clinical flowsheets. Each variable
92 used in our analysis, its definition and source are listed in **eTable 1**. There were no
93 missing data for the exposure or outcome variables. Encounters with missing data on
94 covariates in the propensity score model were excluded.

95

96 *Inclusion and Exclusion Criteria*

97 We included patients ≥ 18 years-old presenting to the University of Michigan adult
98 emergency department (ED) between 1/2018-12/2022 who received HFNC or NIV
99 within 24 hours of ED arrival. To capture acute respiratory failure, we excluded patients
100 who were on chronic home ventilator support, had a tracheostomy, or received non-
101 invasive respiratory support only after extubation. We also excluded patients who had
102 positive SARS-CoV-2 antigen test and clinically suspected COVID-19 infection. At our
103 institution, HFNC was the predominant respiratory support mode used for patients with
104 COVID-19 based on concerns about aerosolization and virus transmission with NIV. A

105 single patient may have had multiple encounters during the study period; each
106 encounter was considered an individual observation.

107

108 *Data collection and definition of respiratory support mode*

109 We identified patients who received HFNC or NIV within 24 hours of presentation to the
110 ED based on clinical flowsheets. At our institution, respiratory therapists and nurses
111 record respiratory support mode and settings in a flowsheet at least once per hour and
112 whenever mode or setting changes are made. We defined HFNC as any delivery of
113 greater than 20 liters/minute oxygen from a heated, humidified oxygen system. We
114 defined NIV as any non-invasive ventilation mode (continuous positive airway pressure
115 or bilevel positive airway pressure). We classified patients who received more than one
116 non-invasive respiratory support mode during a given hour according to the dominant
117 mode (mode used most frequently) for the hour. For the primary analysis, we classified
118 patients as receiving initial HFNC or NIV if they received those modes exclusively for
119 the first two hours after initiation, to ensure stable initial group assignment.

120

121 *Study Outcomes*

122 The primary outcome was a hierarchical composite outcome of major adverse
123 pulmonary events: 28-day mortality, 28-day ventilator-free days, and hours spent on
124 non-invasive respiratory support from initiation through hour 72. The primary outcome
125 was calculated using a Win Ratio (see *Data Analysis* below for details). We also
126 evaluated the components of the composite major adverse pulmonary events outcome

127 individually: mortality and time to death (28-day and in-hospital), intubation rate,
128 ventilator-free days, and non-invasive respiratory support hours.

129

130 *Data Analysis*

131 We used a logistic regression model to calculate a propensity score for the odds of
132 receiving NIV using pre-specified patient characteristics typically available at the time of
133 initiation of HFNC or NIV: age, sex, body mass index, Charlson comorbidity index,
134 history of congestive heart failure, chronic obstructive pulmonary disease (COPD), or
135 obstructive sleep apnea, comparison of measured pCO₂ by blood gas (venous or
136 arterial) to expected pCO₂ by Winter's formula, time from ED arrival to HFNC or NIV
137 initiation, initial lactate, initial Glasgow Coma Score, and highest day 1 sequential organ
138 failure assessment (SOFA) score. While SOFA score is not available on ED arrival, it
139 was included in the propensity score model because it provides a surrogate measure for
140 severity of illness. ICD-10 diagnosis codes were recorded to understand etiologies of
141 respiratory failure but were not included in the propensity score model, as discharge-
142 level diagnoses are not available at the time of HFNC or NIV initiation.

143

144 Using the propensity score, we matched patients 1:1 utilizing greedy nearest neighbor
145 matching with calipers set at 0.2 standard deviations.¹⁸ We used standard descriptive
146 statistics, including standard mean differences (SMD) and Kolmogorov-Smirnov
147 statistics, to assess for covariate balance and distribution before and after propensity-
148 score matching. SMD < 0.1 after matching was considered acceptable balance.

149

150 To calculate the primary outcome of major pulmonary adverse events, we used a Win
151 Ratio, a statistical method for combining variables into a hierarichal composite outcome.
152 Unlike typical composite outcomes that assign similar weight to outcomes regardless of
153 their severity (i.e., including both all-cause mortality and need for repeat intervention) or
154 take an “all-or-nothing” approach to evaluating the presence vs absence of an event,
155 the Win Ratio accommodates mixed variable types (e.g., binary, ordinal, continuous,
156 time-to-event) and ranks variables by clinical relevance and patient priorities. Prior
157 literature has defined the calculation of the Win Ratio in detail.¹⁷ In brief, we generated
158 all possible pairs of patients on NIV and HFNC. Pairs were sequentially compared on
159 outcomes based on pre-determined importance: 1) 28-day mortality as a survival event,
160 2) 28-day ventilator-free days, and 3) non-invasive respiratory support hours from
161 initiation to hour 72. We incorporated selective tie-breaking to best parallel clinical
162 reasoning. For example, for two individuals who tied on mortality, we did not compare
163 ventilator-free days or non-invasive respiratory support hours. Total wins and losses
164 were added up across all three outcome tiers and compared to generate the Win Ratio,
165 which was calculated using the WinRatio package (v1.0).¹⁹
166
167 Individual secondary outcomes were compared using Mann-Whitney U tests for
168 continuous variables and Chi-squared tests for categorical variables. Time to death and
169 time to intubation were analyzed using a Kaplan-Meier survival analysis. Hourly
170 respiratory support mode and daily patient status were visualized using stacked
171 histogram plots.
172

173 We conducted several sensitivity analyses: 1) intention-to-treat framework: inclusion of
174 patients who crossed-over between respiratory support modes or had discontinuation of
175 non-invasive respiratory support in the first 2 hours, 2) alternative approaches to
176 calculating the Win Ratio.

177

178 Initial data cleaning, data exploration, and visualization was performed using Tableau
179 (Tableau Software). Final data cleaning and all statistical analyses were performed
180 using R (v4.2.1) in R Studio (v2022.2.3).

181

182 **Results**

183 Between January 2018 and December 2022, 2,208/361,459 (0.6%) adult ED
184 encounters required non-invasive respiratory support within 24 hours of ED arrival. Of
185 these, 1,265/2,208 (57.3%) met study inclusion criteria (**Figure 1**). HFNC was the
186 predominant mode, used in 795/1,265 (62.8%) encounters. Patients treated with NIV
187 and HFNC had large differences in baseline congestive heart failure (78.3% vs 54.5%,
188 SMD 0.52), pCO₂ above expected based on Winter's Formula (67.7% vs 33.7%, SMD
189 0.74), shock index (heart rate/systolic blood pressure: 0.7 vs 0.8, SMD 0.36) and lactate
190 >4 mmol/L (9.8% vs 15.0%, SMD 0.22) (**Table 1**). The most common encounter
191 diagnosis codes were respiratory failure not otherwise specified (89.7% vs 85.5%),
192 followed by volume overload (54.1%) and pneumonia (48.9%) in the HFNC group and
193 volume overload (78.1%) and COPD/asthma exacerbation (52.3%) in NIV group
194 (**eTable 2**).

195

196 In our propensity model, (**eFigure 1**) body mass index (Odds Ratio (OR) 1.03 [per kg/m²
197 increase], 95%CI: 1.02-1.05), history of congestive heart failure (OR 2.29, 95%CI: 1.70-
198 3.11), and pCO₂ above expected by Winter's formula (OR 3.49, 95%CI: 2.48-4.96)
199 were associated with increased odds of treatment with NIV, while hemodynamic
200 instability (shock index: OR 0.46 [per unit increase], 95%CI: 0.26-0.82) and higher
201 SOFA (OR 0.91 [per point increase], 95%CI: 0.86-0.96) were associated with lower
202 odds of receiving NIV.

203

204 We matched 736/1,265 (58.1%) eligible patients at a ratio of 1:1, including 368/795
205 (45.9%) on HFNC and 368/470 (78.3%) on NIV. Patient characteristics were well-
206 balanced between groups after matching, with all SMDs <0.1 except body mass index
207 (SMD 0.109) (**Table 1, eFigure 2**). Matched NIV patients were similar to overall NIV
208 patients, while matched HFNC patients had higher rates of congestive heart failure,
209 higher body mass index, and more pCO₂ above expected by Winter's formula than
210 overall HFNC patients (**Table 1**).

211

212 The primary outcome was major adverse pulmonary events. We first evaluated
213 individual components of the major adverse pulmonary events outcome (**Table 2**).

214 There was no difference between patients treated with NIV vs HFNC in 28-day mortality
215 (17.7% vs 23.1%, p=0.08) or ventilator-free days (median [IQR]: 28 [25,28] vs 28 [13,
216 28], p=0.50). However, patients treated with NIV spent significantly fewer hours on non-
217 invasive respiratory support within the first 72 hours of initiation (median 7 vs 13 hours,
218 p<0.001). Hourly respiratory support modes up to 72 hours post-HFNC or NIV initiation

219 and daily patient status out to 28 days by treatment group are presented in the
220 supplement (**eFigure 3 and 4**). Time to death by 28 days was also similar between
221 patients treated with NIV vs HFNC (**eFigure 5**).

222

223 We then calculated the composite major adverse pulmonary events using the Win
224 Ratio. There were 135,424 potential matched patient pairs (368x368). In total, NIV won
225 in 74,008 (54.6%) pairs while HFNC won in 58,957 (43.5%), resulting in a Win Ratio for
226 NIV of 1.26 (95% CI: 1.06-1.49, $p=0.009$). NIV won over HFNC for 28-day mortality
227 (wins, as percent of all pairs: 20.8% vs 15.8%) and NIRS hours (wins: 23.7% vs 14.7%),
228 but not ventilator-free days (wins: 10.1% vs 13.0%). Only 2,459 (1.8%) pairs tied on all
229 tiers (**Table 2, Figure 2**) Results were robust to sensitivity analyses including patients
230 with early respiratory mode cross-over and discontinuation (**eTable 3**) and alternative
231 approaches to Win Ratio calculation (**eTable 4**).

232

233 **Discussion**

234 In this propensity matched retrospective study of patients with acute hypoxemic
235 respiratory failure, initial treatment with NIV decreased time spent on non-invasive
236 respiratory support in the first 72 hours but did not have a significant impact on
237 individual outcomes of mortality or ventilator-free days. However, treatment with NIV
238 was associated with lower composite major adverse pulmonary events, calculated using
239 a Win Ratio.

240

241 Our finding that initial treatment with NIV may decrease overall major adverse
242 pulmonary events compared to HFNC contrasts with the findings of the prominent
243 FLORALI trial. In that trial, HFNC improved mortality and ventilator-free days compared
244 to NIV.¹³ Unfortunately, the results of the FLORALI trial have not been replicated
245 consistently in the few other trials that have compared HFNC and NIV in acute
246 hypoxemic respiratory failure.^{3,4,14,15,20} The failure to replicate these results may be due
247 to limitations of the FLORALI trial (small sample size with potentially high fragility index)
248 and/or due to differences in patient populations enrolled across studies. For example,
249 while our study included all patients receiving HFNC or NIV within 24 hours of ED
250 arrival, the FLORALI trial enrolled a much narrower population of ICU patients with pure
251 hypoxemic respiratory failure, excluding patients with hypercarbia, cardiogenic
252 pulmonary edema, or COPD exacerbations.¹³ HFNC and NIV have not been directly
253 compared in these other conditions (i.e., heart failure and COPD exacerbations), where
254 recommendations to use NIV are based on comparisons of NIV to low-flow oxygen not
255 HFNC.^{3,11}
256
257 There has only been one trial comparing HFNC vs NIV in a broad population of
258 patients.¹² Similar to our study, that trial by Doshi *et al* enrolled ED patients with acute
259 hypoxemic respiratory failure and found HFNC was non-inferior to NIV based on
260 intubation rates, though the trial was small and not powered to assess other outcomes.
261 Therefore, the optimal non-invasive respiratory support mode for treating early,
262 undifferentiated hypoxemic respiratory failure remains unclear. Our results add to
263 clinical equipoise by suggesting that initial use of NIV may improve outcomes compared

264 to HFNC in the broader population of patients with early, undifferentiated hypoxemic
265 respiratory failure.

266

267 Understanding the optimal initial treatment for undifferentiated hypoxemic respiratory
268 failure is critical, particularly in the ED, where the choice between HFNC and NIV often
269 must be made before information about a patient's diagnosis is fully available. Indeed,
270 our findings suggest that in practice patients frequently have multiple risk factors for
271 respiratory failure. For example, even among the patients who received HFNC, over half
272 had a documented history of heart failure and/or COPD. While the frequency of these
273 comorbidities may be high due to our institution's role as a tertiary referral center, this
274 finding suggests that it may be challenging to identify patients with specific etiologies of
275 respiratory failure in real time. This is further reflected by the mix of encounter diagnosis
276 codes in our cohort, which suggest many patients had mixed etiologies of respiratory
277 failure.

278

279 Our results underscore the need for a randomized controlled trial to further understand
280 the impact of NIV vs HFNC in patients with early, undifferentiated hypoxemic respiratory
281 failure. In order to best inform practice decisions, such trials must employ novel design
282 approaches, such as exemption from informed consent and pragmatic designs²¹, to
283 capture patients early in their disease course, ideally in the ED at the time of NIV or
284 HFNC initiation. Future clinical trials must also select appropriate outcomes to
285 overcome the limitations of potentially subjective primary outcomes, such as intubation
286 or ventilator-free days.

287

288 Our study suggests that use of a Win Ratio may be a feasible approach to using
289 composite outcomes in future studies of respiratory support modes. In our study,
290 calculating the composite outcome of major adverse pulmonary events using a Win
291 Ratio allowed a more nuanced understanding of the impact of NIV and HFNC on patient
292 outcomes than individual outcomes alone. At the individual outcome level, we found no
293 association between respiratory support mode and mortality or ventilator-free days. In
294 contrast, based on the composite outcome of major adverse pulmonary events
295 calculated using a Win Ratio, NIV was superior to HFNC overall and at the mortality and
296 respiratory support hour tiers. These findings highlight one challenge of studies of
297 respiratory failure: the limitations of single outcomes such as mortality or intubation,
298 which can obscure other clinically important outcomes particularly when only a subset of
299 patients experience death or intubation. For example, in our study, a majority of patients
300 survived and were never intubated, but patients treated initially with NIV spent less total
301 time on non-invasive respiratory support. Given both HFNC and NIV require ICU level
302 support at many institutions, spending less time on these devices is a potentially
303 important outcome in patients who survive and are not intubated. Additionally, decisions
304 about intubation and extubation are often subjective¹⁶, limiting the utility of intubation
305 and ventilator-free days as primary outcomes. The Win Ratio offers a mechanism to
306 compare multiple relevant patient outcomes, while maintaining a hierarchical approach
307 that reflects the relative importance of outcomes to patients and their families: first
308 comparing mortality, then ventilator-free days, then non-invasive respiratory support

309 hours. Our results suggest that a similar Win Ratio could be used as a primary outcome
310 for future clinical trials comparing respiratory support modalities.

311

312 *Limitations*

313 This study has several limitations common to retrospective studies. First, there is a risk
314 that our findings are the result of residual confounding. The use of propensity score
315 matching limits that risk, but the presence of confounding on unmeasured variables
316 remains possible and a prospective clinical trial is needed to verify these findings.

317 Secondly, the assignment of the exposure group required that patients receive HFNC or
318 NIV exclusively for the first two hours after initiation, which may limit generalizability to
319 patients who switch support modalities or discontinue them within the first two hours.

320 However, in sensitivity analyses where the exposure group was assigned by first
321 modality, a similar result was observed. Finally, as a single-center study performed at a
322 tertiary care hospital, generalizability may be limited as practice patterns regarding
323 HFNC and NIV use may differ at other centers. While indications for HFNC and NIV
324 selection may vary across institutions, propensity matching helps ensure that the
325 patients included in our study were similar and might be candidates for either HFNC or
326 NIV more broadly.

327

328 **Conclusion**

329 In this propensity matched retrospective study of patients with early acute hypoxemic
330 respiratory failure, initial treatment with NIV was superior to HFNC for major adverse
331 pulmonary events, calculated using a Win Ratio. These results underscore the need for

332 novel randomized controlled trials to definitively determine the merits of each non-
333 invasive respiratory support strategy.

Acknowledgements


This material is the result of work supported with resources and the use of facilities at the Ann Arbor VA Medical Center.

References

1. Behrendt CE. Acute Respiratory Failure in the United States. *Chest*. 2000;118(4):1100-1105. doi:10.1378/chest.118.4.1100
2. Kempker JA, Abril MK, Chen Y, Kramer MR, Waller LA, Martin GS. The Epidemiology of Respiratory Failure in the United States 2002–2017: A Serial Cross-Sectional Study. *Crit Care Explor*. 2020;2(6):e0128. doi:10.1097/CCE.000000000000128
3. Grasselli G, Calfee CS, Camporota L, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. *Intensive Care Med*. Published online June 16, 2023. doi:10.1007/s00134-023-07050-7
4. Nair PR, Haritha D, Behera S, et al. Comparison of High-Flow Nasal Cannula and Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure Due to Severe COVID-19 Pneumonia. *Respir Care*. 2021;66(12):1824-1830. doi:10.4187/respcare.09130
5. Al Hashim AH, Al Reesi A, Al Lawati NM, et al. Comparison of Noninvasive Mechanical Ventilation With High-Flow Nasal Cannula, Face-Mask, and Helmet in Hypoxemic Respiratory Failure in Patients With COVID-19: A Randomized Controlled Trial. *Crit Care Med*. 2023; Publish Ahead of Print. doi:10.1097/CCM.0000000000005963
6. Grieco DL, Menga LS, Eleuteri D, Antonelli M. Patient self-inflicted lung injury: implications for acute hypoxemic respiratory failure and ARDS patients on non-invasive support. *Minerva Anestesiol*. 2019;85(9). doi:10.23736/S0375-9393.19.13418-9
7. Carteaux G, Parfait M, Combet M, Haudebourg AF, Tuffet S, Mekontso Dessap A. Patient-Self Inflicted Lung Injury: A Practical Review. *J Clin Med*. 2021;10(12):2738. doi:10.3390/jcm10122738
8. Sun J, Li Y, Ling B, et al. High flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: an observational cohort study. *Int J Chron Obstruct Pulmon Dis*. 2019; Volume 14:1229-1237. doi:10.2147/COPD.S206567
9. Mauri T, Turrini C, Eronia N, et al. Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure. *Am J Respir Crit Care Med*. 2017;195(9):1207-1215. doi:10.1164/rccm.201605-0916OC
10. Nishimura M. High-Flow Nasal Cannula Oxygen Therapy Devices. *Respir Care*. 2019;64(6):735-742. doi:10.4187/respcare.06718

11. Rochweg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. *Eur Respir J*. 2017;50(2):1602426. doi:10.1183/13993003.02426-2016
12. Doshi P, Whittle JS, Bublewicz M, et al. High-Velocity Nasal Insufflation in the Treatment of Respiratory Failure: A Randomized Clinical Trial. *Ann Emerg Med*. 2018;72(1):73-83.e5. doi:10.1016/j.annemergmed.2017.12.006
13. Frat JP, Thille AW, Mercat A, et al. High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure. *N Engl J Med*. 2015;372(23):2185-2196. doi:10.1056/NEJMoa1503326
14. Coudroy R, Frat JP, Ehrmann S, et al. High-flow nasal oxygen alone or alternating with non-invasive ventilation in critically ill immunocompromised patients with acute respiratory failure: a randomised controlled trial. *Lancet Respir Med*. 2022;10(7):641-649. doi:10.1016/S2213-2600(22)00096-0
15. Grieco DL, Menga LS, Cesarano M, et al. Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial. *JAMA*. 2021;325(17):1731. doi:10.1001/jama.2021.4682
16. Yarnell CJ, Johnson A, Dam T, et al. Do Thresholds for Invasive Ventilation in Hypoxemic Respiratory Failure Exist? A Cohort Study. *Am J Respir Crit Care Med*. 2023;207(3):271-282. doi:10.1164/rccm.202206-1092OC
17. Redfors B, Gregson J, Crowley A, et al. The win ratio approach for composite endpoints: practical guidance based on previous experience. *Eur Heart J*. 2020;41(46):4391-4399. doi:10.1093/eurheartj/ehaa665
18. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivar Behav Res*. 2011;46(3):399-424. doi:10.1080/00273171.2011.568786
19. Git Hub, Inc. Win Ratio Applications. Published 2023. Accessed August 15, 2023. <https://github.com/CRF-Biostatistics/WinRatioApplications>
20. Perkins GD, Ji C, Connolly BA, et al. Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial. *JAMA*. 2022;327(6):546. doi:10.1001/jama.2022.0028
21. Casey JD, Beskow LM, Brown J, et al. Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. *Lancet Respir Med*. 2022;10(7):700-714. doi:10.1016/S2213-2600(22)00044-3

Figure 1. Study Flow Diagram



¹NIRS = Non-invasive respiratory support (either HFNC or NIV)

²Chronic assisted ventilation based on vent mode, respiratory therapy documentation, or ICD-10


³Patients received NIRS after extubation within 24 hours of ED arrival

⁴Recent Covid-19 PCR positive and clinically considered positive

⁵Any crossover between HFNC and NIV within 2 hours of initiation

Figure 1 Legend: Study flow diagram. The primary analysis included N=1,265 patients in the pool for matching. A sensitivity analysis was performed for all patients receiving qualifying non-invasive respiratory support (NIRS), including early cross-over and discontinuation (N=1,615, see eTable 1). **Definitions:** ED= Emergency Department, O2= oxygen, L= liter, NIRS= non-invasive respiratory support, which includes both high-flow nasal cannula and non-invasive ventilation, vent= ventilation, HFNC= high-flow nasal canula, NIV= non-invasive ventilation, which includes continuous positive airway pressure and bilevel positive airway pressure.

Figure 2. Visualization of the Win Ratio of Major Adverse Pulmonary Events



$$\text{Win ratio} = \frac{54.6\%}{43.5\%} = 1.26 \quad 95\% \text{ CI: } 1.06\text{-}1.49, p < 0.001$$

Figure 2 Legend. Comparison of Major Pulmonary Adverse Events between NIV and HFNC using the Win Ratio. The Win Ratio is the ratio of overall “wins for NIV” over “wins for HFNC.” A positive Win Ratio suggests NIV results in a better composite outcome compared to HFNC. Percentages represent the percent of pairs out of the total possible pairs. On tier 1 (time to death) and overall, the percentages sum to 100% because all patient pairs are compared at these levels. However, tiers 2 and 3 only compare patients who tied on the previous tier. For example, in tier 2 (ventilator-free days), the percentages add to the number of patients who tied on the previous tier (63.3%).

Definitions: Non-invasive respiratory support hours = time spent on non-invasive respiratory support (NIV or HFNC) in hours, from initiation through hour 72. NIV= non-invasive ventilation. HFNC= high-flow nasal cannula.

Table 1. Baseline patient characteristics before and after propensity score matching						
	Overall Cohort			Matched Cohort		
	HFNC (n=795)	NIV (n=470)	SMD	HFNC (n = 368)	NIV (n = 368)	SMD
Age, year	66.7 [55.4, 75.7]	68.9 [59.6, 77.6]	0.218	69.4 [57.1, 78.2]	68.3 [59.0, 77.6]	0.031
Male sex	466 (58.6)	245 (52.1)	0.131	194 (52.7)	199 (54.1)	0.027
Body Mass Index, kg/m ²	26.3 [22.1, 31.2]	29.0 [23.6, 35.5]	0.395	27.4 [23.1, 32.9]	27.5 [23.0, 34.3]	0.109
Charlson Comorbidity Index	8.0 [4.0, 14.0]	9.0 [5.0, 14.0]	0.154	8.0 [4.0, 14.0]	8.5 [5.0, 14.0]	0.047
Individual comorbidities at baseline						
Congestive heart failure	433 (54.5)	368 (78.3)	0.521	264 (71.7)	266 (72.3)	0.012
Chronic obstructive pulmonary disease	482 (60.6)	326 (69.4)	0.184	246 (66.8)	246 (66.8)	<0.001
Obstructive sleep apnea	160 (20.1)	132 (28.1)	0.187	86 (23.4)	96 (26.1)	0.063
Expected pCO ₂ *						
pCO ₂ at expected	184 (23.1)	70 (14.9)	0.74	70 (19.0)	68 (18.5)	0.065
pCO ₂ above expected	268 (33.7)	318 (67.7)		207 (56.2)	218 (59.2)	
pCO ₂ below expected	343 (43.1)	82 (17.4)		91 (24.7)	82 (22.3)	
First hours of non-invasive respiratory support	2.0 [1.0, 7.0]	2.0 [1.0, 4.8]	0.272	2.0 [1.0, 5.0]	2.0 [1.0, 5.0]	0.026
Systolic shock index	0.8 [0.7, 1.0]	0.7 [0.5, 0.9]	0.362	0.7 [0.6, 0.9]	0.7 [0.6, 0.9]	0.020
Lactate group, n(%)						
< 2 mmol/L	415 (52.2)	293 (62.3)	0.22	210 (57.1)	220 (59.8)	0.058
2-4 mmol/L	261 (32.8)	131 (27.9)		102 (29.6)	104 (28.3)	
>4 mmol/L	119 (15.0)	46 (9.8)		49 (13.3)	44 (12.0)	
Glasgow Coma Score	15 [15, 15]	15 [15, 15]	0.106	15 [15, 15]	15 [15, 15]	0.095
Highest Day 1 SOFA	5.0 [4.0, 7.0]	5.0 [3.0, 6.0]	0.275	5.0 [4.0, 6.0]	5.0 [4.0, 7.0]	0.016

Table 1 Legend: Baseline characteristics in the overall cohort and matched study cohort. Data are presented as median [IQR] and N(%). *Expected pCO₂ was calculated using the first available bicarbonate from a basic metabolic panel and pCO₂ from the first arterial or venous blood gas, comparing actual pCO₂ to pCO₂ that would be expected based on Winter's formula. pCO₂ above expected suggests superimposed respiratory alkalosis, while pCO₂ below expected suggests superimposed respiratory acidosis. Patients were matched on calculated expected pCO₂, not individual pH, pCO₂, or bicarbonate values.

Definitions: HFNC= high flow nasal cannula, NIV= non-invasive positive pressure ventilation, SMD= standard mean difference, systolic shock index= ratio of heart rate / blood pressure, SOFA= sequential organ failure assessment. Non-invasive respiratory support refers to both HFNC and NIV.

Table 2. Individual outcomes for patients receiving HFNC vs NIV in the overall and matched cohort						
	Overall Cohort			Matched		
	HFNC (n=795)	NIV (n=470)	p-value	HFNC (n = 368)	NIV (n = 368)	p-value
28-day mortality, n (%)	215 (27.0)	74 (15.7)	<0.001	85 (23.1)	65 (17.7)	0.082
Time to death in 28-days, median days [IQR]	6.8 [3.1, 14.2]	6.2 [2.7, 13.0]	0.539	7.2 [3.1, 16.2]	6.1 [2.7, 12.9]	0.280
In-hospital mortality, n (%)	169 (21.3)	58 (12.3)	<0.001	64 (17.4)	51 (13.9)	0.223
Time to death in hospital, median days [IQR]	5.2 [2.4, 12.5]	4.2 [2.2, 8.9]	0.415	5.5 [2.5, 13.6]	4.0 [2.2, 9.5]	0.406
Intubation within 72 hours of HFNC or NIV initiation, n (%)	160 (20.1)	68 (14.5)	0.014	57 (15.5)	57 (15.5)	1.00
Ventilator-free days, median [IQR]	28.0 [0.0, 28.0]	28.0 [26.0, 28.0]	<0.001	28.0 [12.8, 28.0]	28.0 [25.0, 28.0]	0.497
Non-invasive respiratory support hours, median [IQR]	14.0 [6.0, 34.0]	8.0 [4.0, 26.3]	<0.001	13.0 [6.0, 33.0]	7.0 [4.0, 14.0]	<0.001

Table 2 Legend. Individual patient outcomes before and after propensity score matching. Data are presented as n(%) and median [IQR]. p-values were calculated using Mann-Whitney U for continuous variables and Chi-squared test for categorical variables. Grey rows represent outcomes that contribute to the primary composite Major Adverse Pulmonary Events outcome. Ventilator-free days were calculated from admission through day 28. Non-invasive respiratory support hours were hours spent on HFNC or NIV calculated from initiation through hour 72.

Definitions: HFNC= high flow nasal cannula, NIV= non-invasive positive pressure ventilation.

Table 3. Win Ratio of composite Major Adverse Pulmonary Events for patients receiving HFNC vs NIV							
Tier	Outcome	Overall Cohort			Matched Cohort		
		NIV wins	HFNC wins	Ties	NIV wins	HFNC wins	Ties
1	Time to death (28-day mortality)	92,713 (24.8%)	51,255 (13.7%)	229,682 (61.5%)	28,232 (20.8%)	21,442 (15.8%)	85,750 (63.3%)
2	Ventilator-free days	45,921 (12.3%)	42,225 (11.3%)	141,536 (37.9%)	13,615 (10.0%)	17,589 (13.0%)	54,546 (40.2%)
3	Non-invasive respiratory support hours	87,343 (23.4%)	48,011 (12.8%)	6,182 (1.7%)	32,161 (23.7%)	19,926 (14.7%)	2,459 (1.8%)
	Totals, by category	225,977 (60.5%)	141,491 (37.9%)	6,182 (1.7%)	74,008 (54.6%)	58,957 (43.5%)	2,459 (1.8%)
	Total possible pairs	373,650			135,424		
	Win Ratio (95% CI), p-value	1.60 (1.39- 1.83), p <0.001			1.26 (1.06 -1.49), p=0.009		

Table 3 Legend. Details of the Win Ratio used to calculate the composite Major Adverse Pulmonary Events in the overall cohort (N=1,265) and in the matched study cohort (N=736). The Win Ratio in the matched cohort is the primary outcome, which is also displayed visually in Figure 2.

The Win Ratio is the ratio of overall “wins for NIV” over “wins for HFNC.” A positive Win Ratio suggests NIV results in a better composite outcome compared to HFNC. Percentages represent the percent of pairs out of the total possible pairs. On tier 1 (time to death) and overall, the percentages sum to 100% because all patient pairs are compared at these levels. However, tiers 2 and 3 only compare patients who tied on the previous tier. For example, in tier 2 (ventilator-free days), the percentages add to the number of patients who tied on the previous tier.

Definitions: HFNC= high flow nasal cannula, NIV= non-invasive positive pressure ventilation. Ventilator-free days were calculated from admission through day 28. Non-invasive respiratory support hours were hours spent on HFNC or NIV calculated from initiation through hour 72.